(ETON) Eton Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29772L1089
ETON: Hormone Replacement, Acid Treatment, Amino Acid Therapy, Crisis Injector
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company specializing in the development, acquisition, and commercialization of treatments for rare diseases. Its product portfolio includes ALKINDI SPRINKLE, the first and only FDA-approved sprinkle formulation for hydrocortisone, designed for pediatric adrenocortical insufficiency; Carglumic Acid, an orphan drug for N-acetylglutamate synthase deficiency; Betaine Anhydrous, addressing homocystinuria; and Nitisinone, a life-long treatment for hereditary tyrosinemia type 1. The company also markets Zeneo, a hydrocortisone autoinjector for acute adrenal crisis. Since its inception in 2017, Eton has focused on improving patient access to critical therapies through its targeted pipeline and commercial strategy.
From a stock perspective, ETON is trading at $15.70 with a 20-day average volume of 286,603 shares. The stock has shown upward momentum, with a 20-day SMA of 16.27 and a 50-day SMA of 14.89, reflecting recent strength. The 200-day SMA of 8.20 highlights significant growth over the past year. With an ATR of 1.08, volatility remains moderate. Fundamentally, ETON has a market cap of $236.92M, a forward P/E of 17.92, and a P/S ratio of 10.90, indicating a rich valuation. The negative RoE of -34.30% reflects current losses but may improve as revenues scale.
3-Month Forecast: Based onAdditional Sources for ETON Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ETON Stock Overview
Market Cap in USD | 237m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2018-11-13 |
ETON Stock Ratings
Growth 5y | 48.7% |
Fundamental | -28.1% |
Dividend | 0.0% |
Rel. Strength Industry | 246 |
Analysts | 4.67/5 |
Fair Price Momentum | 14.31 USD |
Fair Price DCF | 0.63 USD |
ETON Dividends
No Dividends PaidETON Growth Ratios
Growth Correlation 3m | 59.1% |
Growth Correlation 12m | 90.7% |
Growth Correlation 5y | -18.4% |
CAGR 5y | 38.04% |
CAGR/Max DD 5y | 0.48 |
Sharpe Ratio 12m | 1.38 |
Alpha | 237.34 |
Beta | 1.20 |
Volatility | 72.74% |
Current Volume | 191k |
Average Volume 20d | 209.8k |
As of March 15, 2025, the stock is trading at USD 15.58 with a total of 191,027 shares traded.
Over the past week, the price has changed by +6.79%, over one month by -5.09%, over three months by +22.29% and over the past year by +249.33%.
Probably not. Based on ValueRay Fundamental Analyses, Eton Pharmaceuticals (NASDAQ:ETON) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.05 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ETON as of March 2025 is 14.31. This means that ETON is currently overvalued and has a potential downside of -8.15%.
Eton Pharmaceuticals has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy ETON.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ETON Eton Pharmaceuticals will be worth about 16.1 in March 2026. The stock is currently trading at 15.58. This means that the stock has a potential upside of +3.47%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 13 | -16.6% |
Analysts Target Price | 13 | -16.6% |
ValueRay Target Price | 16.1 | 3.5% |